.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL03_Zanubrutinib.Zanubrutinib

Information

Zanubrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies such as mantle cell lymphoma, Waldenström's macroglobulinemia, and chronic lymphocytic leukemia. It has received FDA approval for certain hematological cancers.

Pharmacokinetics

Pharmacokinetic parameters reported for patients with B-cell malignancies following oral administration of zanubrutinib at a dose of 160 mg, twice daily. Data primarily from adult patients.

References

1. Mu, S, et al., & Sahasranaman, S (2020). Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer chemotherapy and pharmacology 85(2) 391–399. DOI:10.1007/s00280-019-04015-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31875923

Revisions

• 06/2025 initial generated model